loader
Please Wait
Applying Filters...
FDA-DMF-Filings-in-2019
X

List of Active Pharmaceutical Ingredients (APIs) supplied/manufactured by Pcas

Client EmailClient Virtual Booth
Filters Filter
×
FILTER DATA :

filter

filter

ARTICAINE HYDROCHLORIDE

Baclofen

Cicletanine

Ciclopirox

Ciclopirox Olamine

Cinacalcet

Clomifene Citrate

Clonidine

Deferasirox

Desipramine Hydrochloride

Divalproex Sodium

Droxidopa

ESOMEPRAZOLE SODIUM

Enclomiphene citrate

Esomeprazole Magnesium

Glycopyrrolate

Heptaminol

Mepenzolic Acid

Mepivacaine

Methenamine Hippurate

Mirabegron

Moexipril

Norpace

Ospemifene

Oxybutynin

P-Aminoclonidine Hydrochloride

Pholcodine

Pindolol

Praziquantel

Promazine

Promethazine

Rufinamide

TOREMIFENE CITRATE

Tamoxifen Citrate

Tazarotene

Tetrahydrozoline

Timolol

Timolol Maleate

Trimeprazine Tartrate

Troxerutin

Ulipristal

l-Baclofen

mequitazine

olopatadine hydrochloride

piperidolate hydrochloride

filter

FRANCE

With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology ...
With close to 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. Boasting especially high standards, PCAS generated net sales of €179,1 million in 2015 and employs more than 900 people in six countries.

PharmaCompass >>

First
Previous
Next
Last